Optimum Client’s Win Big at LSX European Lifestars Awards! Congratulations to Optimum’s clients – Asceneuron SA, Calliditas Therapeutics, DISCO Pharmaceuticals GmbH, Sofinnova Partners portfolio company Moon Surgical, Myricx Bio, and Novo Holdings, all of whom took home LSX European Lifestars awards! Plus, a special moment for Optimum’s Zoe Bolt who presented the award for Private […]
Pioneering Rosalind study aims to transform cancer treatment with insights from ‘super-responder’ patients Tumor samples from over 1,000 cancer survivors across three aggressive types will be analyzed for genetics and biomarkers Findings will enrich Cure51’s multi-omics database to advance new biology and precision medicine tools Paris, France, 18 November 2024 – Cure51, a techbio company […]
Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments PARIS, France – September 10, 2024 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also […]
The first panel of the day, chaired by Mary Clark, our co-founder and CEO, saw a group of Europe’s leading investors – Hakan Goker, M Ventures; Maina Bhaman, Sofinnova Partners; Christian Elling, Lundbeckfonden; and Roel Bulthuis, Syncona – share sage advice for companies looking to raise funds, providing insights on the most important factors shaping […]
Melanie Senior’s article in Nature Portfolio on ‘Precision Financing’ highlights the rigour behind private biotech financing in 2023 where strong data and efficiency are essential. Two of our clients, Naveed Siddiqi of Novo Holdings and Antoine Papiernik from Sofinnova Partners were featured. Here are some key takeaways… Since the pandemic, the biotech industry has experienced […]
